Cost-effectiveness analysis of sugemalimab plus chemotherapy for the first-line treatment of advanced gastric cancer or gastroesophageal junction cancer.

ABSTRACT: The GEMSTONE-303 trial demonstrated the significant efficacy and safety of sugemalimab plus chemotherapy (S + C) as first-line treatment for patients with advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC). To evaluate the cost-effectiveness of S + C for advanced GC/GEJC from the perspective of the Chinese healthcare system. A partitioned survival model with a 3-week cycle was created to evaluate the cost-effectiveness of S + C compared to placebo plus chemotherapy (P + C) as the first-line treatment for advanced GC/GEJC. Total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) as the primary outputs. Sensitivity analyses were performed to evaluate the uncertainty and stability of model parameters. Additionally, subgroup and s

SUBMITTER: Yan C 

PROVIDER: S-EPMC12802978 | biostudies-literature | 2026 Dec

REPOSITORIES: biostudies-literature